

OptiGene Limited signed License Agreement on the licensing of LAMP technology from Eiken Chemical Co., Ltd.

OptiGene Limited has signed a License Agreement to enter into the licensing of Eiken's own innovative gene amplification technology (LAMP method).

OptiGene Limited has been developing instrumentation and reagents that support amplification and detection of DNA and RNA. The Horsham-based company has a wealth of experience, not only in instrument design and manufacture, but also in the research and development of novel chemistries and reagent systems.

Conclusion of this License Agreement enables OptiGene to develop, manufacture and sell nucleic acid amplification reagents for research use.

OptiGene has adopted Isothermal Amplification with the benefits of single temperature operation and no need for thermal cycling. Therefore, the user is not reliant upon expensive cyclers and in many cases no DNA extraction is necessary.

The Genie II instrument offers ultra-rapid amplification together with highly sensitive fluorescence detection within a single integrated platform and is a truly portable amplification platform. The instrument has an A4 footprint, and can operate from an internal battery or an external power source, so the system really is suitable for 'point of use' applications.

When linked with OptiGene's proprietary fast reagents time to result can be extremely rapid with target detection in as low as ten minutes or less for some applications. Consequently, this is a genuine alternative to PCR.

"Other techniques can be used to identify certain pathogens in the field, but identification at the species level requires a nucleic acid-based approach.", said Duncan Clark, Director of OptiGene Limited. "The Genie II instrument, along with our reagents, satisfies the need for a practical and viable detection method."